Phase I/II Combination With Irinotecan- Erbitux

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Part 1: To define the recommended dose of brivanib that can be safely administered in combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic colorectal cancer (MCRC)

Part 2: To compare median duration of progression free survival (PFS)

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Camptothecin; Cetuximab; Irinotecan

Criteria

Inclusion Criteria:

• Biopsy proven MCRC

• Prior irinotecan allowed

• Prior Erbitux allowed

Exclusion Criteria:

• No prior brivanib

• No prior combination of irinotecan with Erbitux

• No secondary malignancies

• No anti-coagulation therapy

• No prior history of blood clots requiring anti-coagulation